SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03671525

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Cognitive Effects of Nimodipine in Patients With Schizophrenia

This study aims to evaluate the acute effects of nimodipine on cognitive performance in patients with schizophrenia using a battery of cognitive assessments.The subjects will also complete a 30-minute structural and functional MRI scan, with the goal of linking brain activity with working memory performance. Investigators predict that the performance increase induced by nimodipine will be greater in subjects who carry the A allele for the Calcium Voltage-Gated Channel Subunit Alpha1 C (CACNA1C) risk single nucleotide polymorphism (SNP) (rs1006737) in comparison to the response of G carriers.

NCT03671525 Schizophrenia Schizo Affective Disorder
MeSH: Schizophrenia Mood Disorders Psychotic Disorders
HPO: Psychosis Schizophrenia

2 Interventions

Name: Nimodipine

Description: Subject will receive two 30mg capsules of nimodipine during study visit.

Type: Drug

Nimodipine

Name: Placebo oral capsule

Description: Two coconut oil capsules that mimic the size and color of the nimodipine capsules

Type: Drug

Placebo


Primary Outcomes

Description: participants will complete an MRI scan to link brain activity with cognitive performance. Measures will be recorded in Arbitrary units.

Measure: Brain activity as assessed by BOLD fMRI

Time: between 30 min and 1 hour after dose

Description: Participants will complete the Brief Visuospatial Memory Task - Revised (BVMT-R) before and after administration of drug or placebo to determine the effect of nimodipine on visuospatial memory in patients with schizophrenia. Scores range from 0 to 60, with higher values indicating better performance. Administration takes approximately 45 minutes to complete (including a 25 minute delay)

Measure: Changes in Visual Learning and Memory Score

Time: approximately an hour after dose

Description: During each study visit, participants will complete the Hopkins Verbal Learning Task - Revised (HVLT-R) before and after administration of drug or placebo to determine the effect of nimodipine on verbal learning and memory in patients with schizophrenia. Scores range from 0 to 60, with higher values indicating better performance. Administration takes approximately 35 minutes to complete (including a 20-25 minute delay).

Measure: Changes in Auditory Learning and Memory Score

Time: approximately an hour after dose

Description: During each study visit, participants will complete the Global Neurocognitive Assessment (GNA) before and after administration of drug or placebo to determine the effect of nimodipine on a range of neurocognitive measures in patients with schizophrenia. The GNA contains 10 items with varying score ranges. Higher scores indicate better performance.

Measure: Changes in Global Neurocognitive effect as assessed by the Global Neurocognitive Assessment (GNA)

Time: approximately an hour after dose

Secondary Outcomes

Description: The CACNA1C risk-associated SNP (rs1006737) will be tested using a linear regression (with copy of A alleles) with each cognitive domain score to determine if CACNA1C genetics impact response to nimodipine.

Measure: Effect of CACNA1C genotype on cognitive performance measures

Time: during 2-3 hour study visit

Description: Genetic data will be used more broadly to include testing of the effects of genetic variation including but not limited to schizophrenia, cognition, behavior, and drug metabolism.

Measure: Broader genetic associations with cognitive performance

Time: during 2-3 hour study visit

Purpose: Other

Allocation: Randomized

Crossover Assignment


There is one SNP

SNPs


1 rs1006737

Investigators predict that the performance increase induced by nimodipine will be greater in subjects who carry the A allele for the Calcium Voltage-Gated Channel Subunit Alpha1 C (CACNA1C) risk single nucleotide polymorphism (SNP) (rs1006737) in comparison to the response of G carriers.

The CACNA1C risk-associated SNP (rs1006737) will be tested using a linear regression (with copy of A alleles) with each cognitive domain score to determine if CACNA1C genetics impact response to nimodipine.. Broader genetic associations with cognitive performance.



HPO Nodes


HPO:
Psychosis
Genes 94
NPC1 NHLRC1 MKRN3 SNORD115-1 CACNA1A SLC12A6 CLN8 TMEM106B USP8 PRDM8 EPM2A MAGEL2 PANK2 PSEN1 COX1 COX2 COX3 ACADS PDGFB PDGFRB MAPT ZDHHC9 ATXN7 WFS1 SOBP SQSTM1 SLC20A2 CLN3 PARK7 RPS6KA3 PCDH19 ND1 TBC1D7 ND4 ND5 SLC6A19 ND6 PAH VPS13A NPAP1 TREM2 DCAF17 IPW PRKAR1A PWRN1 PAK3 SPART ALDH18A1 CDH23 HMBS TWNK TRNF ZFYVE26 GRN NPC2 ALAD TRNH NDN NDP UPF3B ABCD1 TRNL1 AIP GNAS PWAR1 HERC2 TRNQ TRNS1 TRNS2 C9ORF72 SLC7A7 TRNW ITM2B ATP13A2 CBS ALDH5A1 MECP2 LMBRD1 KCNT1 SNRPN MED12 SH2B1 SNORD116-1 NAGS PRNP MYORG TTC19 VCP GSS CHMP2B DNMT1 PPOX PDE11A MKRN3-AS1
Schizophrenia
Genes 50
WHRN FLI1 GJA5 GJA8 DNAJC13 CIB2 ARSA PSAP COMT SEC24C CEP78 ARVCF MYO7A ZDHHC9 WFS1 USH1G KRT81 DISC2 KRT83 KRT86 VPS35 UFD1 EIF4G1 LRRK2 PCDH15 GBA CDH23 GIGYF2 TRNE PDZD7 DSG4 UPF3B ADGRV1 HARS SNCA TRNS2 RREB1 USH1C USH2A ATP2A2 CLRN1 JMJD1C MED12 MSTO1 CHRNA7 TBX1 ARSG PRODH HIRA GP1BB